RRAM, an Affiliate of Apollo, to add ~$11 billion of CLO assets bringing total AUM to ~$38 billion Irradiant’s John Eanes Named Incoming CIO of RRAM US NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Redding Ridge Asset Management (RRAM), an independently managed affiliate of Apollo (NYSE: APO), today announced it has agreed to acquire Irradiant Partners, an alternative investment manager specializing in liquid credit, private credit and renewables. As a result of the acquisition, RRAM will add $10.7 billion of CLO AUM, further scaling the business and creating a top five CLO manager with approximately $38 billion of AUM. In addition, Apollo will add $2.2 billion of private credit and renewables AUM from Irradiant. Irradiant was established in 2021 and was founded by Michael Levitt, John Eanes and Jon Levinson. Following close of the...

Barb Fuller joins as Vice President of Luxury to lead strategy and drive brand growthBarbara FullerBarbara Fuller HeadshotBrizoBrizo logoBrizoBrizo Product DisplayNewport BrassNewport Brass Product DisplayNewport BrassNewport Brass LogoINDIANAPOLIS, Feb. 21, 2025 (GLOBE NEWSWIRE) — Delta Faucet Company, a leader in branded kitchen and bathroom products including faucet fixtures, sinks and accessories, is proud to announce the addition of Newport Brass®, a brand known for its high-quality, custom finish brass faucets and fixtures, to its portfolio. This addition enables Delta Faucet Company’s entry into the luxury segment while complementing the ongoing growth of its upper premium brand, Brizo®. This strategic growth initiative strengthens Delta Faucet Company’s ability to serve the...

SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics’ common stock to approve the transaction, which occurred on February 19, 2025, the transaction has now closed. Effective as of closing, Singular Genomics now operates...

Board Approves Exploration of Funding Options for Mergers, Acquisitions, Partnerships SARASOTA, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) — The Board of Directors of Trump Media and Technology Group Corp. (Nasdaq: DJT) (“TMTG” or the “Company”), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, has voted to authorize the Company’s leaders to create a strategic acquisition fund with select investors. The fund’s purpose is to devise and implement financing strategies for possible mergers and acquisitions in accord with TMTG’s existing growth strategy. TMTG is exploring opportunities to partner, merge with and/or acquire other participants in the growing America First Economy that would benefit from the Corporation’s technology and branding—and that...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN’s development programs or intellectual property. On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025,...

This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this press release and in the offer document published on the transaction website (www.raredisease-offer.com). Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this press release. Leiden,...

Deal Marks Expansion Outside of North America Creating a Platform for International Growth NEW YORK and LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) — Bishop Street Underwriters (“Bishop Street”), a RedBird Capital Partners portfolio company, today announced that it has completed its acquisition of Landmark Underwriting (“Landmark”), a specialty-focused managing general agent (“MGA”) based in London. This deal continues Bishop Street’s rapid expansion, growing its investment footprint outside of North America for the first time, and further strengthening the capabilities of its platform. Financial terms of the deal were not disclosed.  As a well-positioned high-growth MGA with an established panel of rated capacity partners, this deal brings Landmark’s specialized and dynamic team to the Bishop Street platform, in support of building...

Tarkett Participation, Tarkett’s controlling shareholder, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the Tarkett shares it does not holdOffer at a price of 16 euros per share, representing a premium of 32.3% and 37.5% over respectively the volume-weighted average share price over the last 20 and 60 trading days Appointment of an ad hoc Committee comprising a majority of independent members of the Supervisory Board, and designation of Finexsi – Expert & Conseil Financier as independent expert Based on a recommendation of its ad hoc Committee, Tarkett’s Supervisory Board has favorably and unanimously welcomed the proposed public buy-out offer followed by a squeeze-outPARIS, FRANCE, February 20, 2025 – Tarkett Participation announces its intention to file in the...

NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) — NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. For immediate release 20 February 2025 HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) Further to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition...